CovidChloroV1, Main, Corpus, bibRecord, 000362

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.

Identifieur interne : 000362 ( Main/Corpus ); précédent : 000361; suivant : 000363

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.

Auteurs : Miguel Angel Martinez

Source :

Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2021.

RBID : pubmed:33558296

English descriptors

KwdEn :
- Animals (MeSH), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (virology), Clinical Trials, Phase I as Topic (MeSH), Clinical Trials, Phase II as Topic (MeSH), Depsipeptides (therapeutic use), Humans (MeSH), Peptides, Cyclic (therapeutic use), SARS-CoV-2 (drug effects).
MESH :
- chemical , therapeutic use : Antiviral Agents, Depsipeptides, Peptides, Cyclic.
- drug effects : SARS-CoV-2.
- drug therapy : COVID-19.
- virology : COVID-19.
- Animals, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Humans.

Abstract

Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta 1a, and remdesivir, have shown that these compounds lack an impact on the COVID-19 course. Although the phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its antiviral activity was 27.5-fold more potent than that of remdesivir (K. M. White, R. Rosales, S. Yildiz, T. Kehrer, et al., Science, 2021, https://science.sciencemag.org/content/early/2021/01/22/science.abf4058). Plitidepsin, a repurposed drug developed for the treatment of multiple myeloma, targets the host translation cofactor eEF1A. Plitidepsin has shown efficacy in animal models and phase I/II human trials. Although plitidepsin is administered intravenously and its toxicity profile remains to be fully characterized, this compound may be a promising alternative COVID-19 therapeutic.

DOI: 10.1128/AAC.00200-21
PubMed: 33558296
PubMed Central: PMC8097422

Links to Exploration step

pubmed:33558296

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.</title>
<author><name sortKey="Martinez, Miguel Angel" sort="Martinez, Miguel Angel" uniqKey="Martinez M" first="Miguel Angel" last="Martinez">Miguel Angel Martinez</name>
<affiliation><nlm:affiliation>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa.es.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33558296</idno>
<idno type="pmid">33558296</idno>
<idno type="doi">10.1128/AAC.00200-21</idno>
<idno type="pmc">PMC8097422</idno>
<idno type="wicri:Area/Main/Corpus">000362</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000362</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.</title>
<author><name sortKey="Martinez, Miguel Angel" sort="Martinez, Miguel Angel" uniqKey="Martinez M" first="Miguel Angel" last="Martinez">Miguel Angel Martinez</name>
<affiliation><nlm:affiliation>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa.es.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (virology)</term>
<term>Clinical Trials, Phase I as Topic (MeSH)</term>
<term>Clinical Trials, Phase II as Topic (MeSH)</term>
<term>Depsipeptides (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Peptides, Cyclic (therapeutic use)</term>
<term>SARS-CoV-2 (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Depsipeptides</term>
<term>Peptides, Cyclic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Clinical Trials, Phase I as Topic</term>
<term>Clinical Trials, Phase II as Topic</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta 1a, and remdesivir, have shown that these compounds lack an impact on the COVID-19 course. Although the phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its antiviral activity was 27.5-fold more potent than that of remdesivir (K. M. White, R. Rosales, S. Yildiz, T. Kehrer, et al., Science, 2021, https://science.sciencemag.org/content/early/2021/01/22/science.abf4058). Plitidepsin, a repurposed drug developed for the treatment of multiple myeloma, targets the host translation cofactor eEF1A. Plitidepsin has shown efficacy in animal models and phase I/II human trials. Although plitidepsin is administered intravenously and its toxicity profile remains to be fully characterized, this compound may be a promising alternative COVID-19 therapeutic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33558296</PMID>
<DateCompleted><Year>2021</Year>
<Month>04</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>65</Volume>
<Issue>4</Issue>
<PubDate><Year>2021</Year>
<Month>03</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e00200-21</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00200-21</ELocationID>
<Abstract><AbstractText>Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta 1a, and remdesivir, have shown that these compounds lack an impact on the COVID-19 course. Although the phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its antiviral activity was 27.5-fold more potent than that of remdesivir (K. M. White, R. Rosales, S. Yildiz, T. Kehrer, et al., Science, 2021, https://science.sciencemag.org/content/early/2021/01/22/science.abf4058). Plitidepsin, a repurposed drug developed for the treatment of multiple myeloma, targets the host translation cofactor eEF1A. Plitidepsin has shown efficacy in animal models and phase I/II human trials. Although plitidepsin is administered intravenously and its toxicity profile remains to be fully characterized, this compound may be a promising alternative COVID-19 therapeutic.</AbstractText>
<CopyrightInformation>Copyright © 2021 American Society for Microbiology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez</LastName>
<ForeName>Miguel Angel</ForeName>
<Initials>MA</Initials>
<Identifier Source="ORCID">0000-0002-6681-4950</Identifier>
<AffiliationInfo><Affiliation>IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa.es.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>03</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047630">Depsipeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Y76ID234HW</RegistryNumber>
<NameOfSubstance UI="C098980">plitidepsin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047630" MajorTopicYN="N">Depsipeptides</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">experimental therapeutics</Keyword>
<Keyword MajorTopicYN="Y">plitidepsin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>2</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>8</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33558296</ArticleId>
<ArticleId IdType="pii">AAC.00200-21</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.00200-21</ArticleId>
<ArticleId IdType="pmc">PMC8097422</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2021 Feb 25;384(8):693-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Oct 19;371:m4057</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33077424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Future Oncol. 2019 Jan;15(2):109-120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30111169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2021 Feb 26;371(6532):926-931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33495306</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Oct;586(7830):516-527</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32967006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Aug 20;64(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32631826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2008 Jul 1;68(13):5216-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18593922</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2021 Feb;27(2):205-211</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33469205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Jul;583(7816):459-468</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32353859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Apr 21;64(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32152082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Dec 16;65(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33139290</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000362 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000362 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33558296
   |texte=   Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33558296" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki